CN115916181A - 非酒精性脂肪性肝炎(nash)的治疗 - Google Patents

非酒精性脂肪性肝炎(nash)的治疗 Download PDF

Info

Publication number
CN115916181A
CN115916181A CN202180049351.XA CN202180049351A CN115916181A CN 115916181 A CN115916181 A CN 115916181A CN 202180049351 A CN202180049351 A CN 202180049351A CN 115916181 A CN115916181 A CN 115916181A
Authority
CN
China
Prior art keywords
salt
25hc3s
nash
subject
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180049351.XA
Other languages
English (en)
Chinese (zh)
Inventor
林伟琦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durect Corp filed Critical Durect Corp
Publication of CN115916181A publication Critical patent/CN115916181A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN202180049351.XA 2020-05-22 2021-05-21 非酒精性脂肪性肝炎(nash)的治疗 Pending CN115916181A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063029361P 2020-05-22 2020-05-22
US63/029,361 2020-05-22
US202063030207P 2020-05-26 2020-05-26
US63/030,207 2020-05-26
US202063113116P 2020-11-12 2020-11-12
US63/113,116 2020-11-12
US202163146555P 2021-02-05 2021-02-05
US63/146,555 2021-02-05
PCT/US2021/033743 WO2021237143A1 (en) 2020-05-22 2021-05-21 Treatment of non-alcoholic steatohepatitis (nash)

Publications (1)

Publication Number Publication Date
CN115916181A true CN115916181A (zh) 2023-04-04

Family

ID=78707644

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180049351.XA Pending CN115916181A (zh) 2020-05-22 2021-05-21 非酒精性脂肪性肝炎(nash)的治疗

Country Status (11)

Country Link
US (1) US20230181601A1 (https=)
EP (1) EP4153164A4 (https=)
JP (1) JP2023527153A (https=)
KR (1) KR20230015939A (https=)
CN (1) CN115916181A (https=)
AU (1) AU2021273936A1 (https=)
BR (1) BR112022022737A2 (https=)
CA (1) CA3195103A1 (https=)
MX (1) MX2022014575A (https=)
TW (1) TW202210081A (https=)
WO (1) WO2021237143A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494125B1 (en) 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US8399441B2 (en) * 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
ES2869884T3 (es) * 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
SG11201507288UA (en) * 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
EP3494125B1 (en) * 2016-08-02 2022-06-22 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US20200222430A1 (en) * 2016-08-02 2020-07-16 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
CN110536682B (zh) * 2017-04-18 2023-01-06 基恩菲特公司 依拉非诺或其衍生物与抗nash、抗纤维化或抗胆汁淤积药剂的组合
KR102419458B1 (ko) * 2017-10-06 2022-07-12 길리애드 사이언시즈, 인코포레이티드 Acc 억제제를 포함하는 조합 요법

Also Published As

Publication number Publication date
KR20230015939A (ko) 2023-01-31
CA3195103A1 (en) 2021-11-25
TW202210081A (zh) 2022-03-16
MX2022014575A (es) 2022-12-15
AU2021273936A1 (en) 2022-12-08
JP2023527153A (ja) 2023-06-27
BR112022022737A2 (pt) 2023-01-31
EP4153164A4 (en) 2024-06-26
US20230181601A1 (en) 2023-06-15
WO2021237143A1 (en) 2021-11-25
EP4153164A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
EP3054940B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
EP2968245B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
Soza et al. Increased orocecal transit time in patients with nonalcoholic fatty liver disease
EA036704B1 (ru) Способ лечения неалкогольной жировой болезни печени и неалкогольного стеатогепатита
EP4142770B1 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
US20260102410A1 (en) Treatment of Alcoholic Hepatitis
US20230181602A1 (en) Treatment of non-alcoholic steatohepatitis (nash)
CN115916181A (zh) 非酒精性脂肪性肝炎(nash)的治疗
EP3716975A1 (en) Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
WO2021237149A2 (en) Treatment of non-alcoholic steatohepatitis (nash)
HK40089967A (zh) 非酒精性脂肪性肝炎(nash)的治疗
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗
US20260097057A1 (en) Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease and liver fibrosis
BR122025021620A2 (pt) Composição compreendendo 25hc3s ou seu sal no tratamento de hepatite alcoólica
HK40073572A (en) Treatment of alcoholic hepatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40089967

Country of ref document: HK